A potassium binder helped people with heart failure and chronic kidney disease reach target medication doses without crossing a blood-potassium threshold. The single peer-reviewed LIFT trial compared treatment with placebo under intensive monitoring. Its short follow-up measured medication escalation, leaving lasting benefits for survival and hospital admissions unresolved.
Science··Night
A binder supports heart-medication escalation
A potassium binder helped patients reach target heart-medication doses while keeping blood potassium below a specified threshold. The single peer-reviewed LIFT study randomly assigned treatment or placebo at a London centre, with assignments concealed from participants and investigators. It enrolled 112 adults with reduced heart-pumping function and advanced chronic kidney disease. Sodium zirconium cyclosilicate was tested as support for existing heart treatment, whose doses can be restricted by rising potassium when kidney function is impaired.[1]
More participants reach the combined target
Follow-up lasted up to 14 weeks. Among participants completing the protocol, 56 per cent receiving the binder reached target doses without blood potassium reaching 5.6 millimoles per litre, compared with 28 per cent receiving placebo. Analysis of all randomized participants also supported a difference. Clinical examinations and laboratory tests took place every two weeks; dose increases depended on blood pressure, potassium measurements and tolerance.[1]
Short follow-up leaves lasting benefit unresolved
The groups showed no significant difference in either overall adverse events or quality of life. The trial was too small and short to establish effects on long-term survival or hospital admissions. Its single-centre setting and intensive monitoring constrain transfer to routine care. A research grant from AstraZeneca financed the work. The investigators reported that design, collection, analysis and interpretation were undertaken without contributions from the funder.[1]
Related columns
For more information on this topic, you can read the related columns.
